https://pro.novonordisk.ae/https://pro.novonordisk.ae/contact-us.htmlhttps://pro.novonordisk.ae/contact-us/contact-us-privacy-notice.htmlhttps://pro.novonordisk.ae/contact-us/report-a-suspected-misconduct-to-the-compliance-hotline.htmlhttps://pro.novonordisk.ae/disease-area.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/the-science-behind-obesity.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/the-science-behind-obesity/disease-understanding.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/the-science-behind-obesity/disease-understanding/appetite-and-body-weight-are-influenced-by-behaviour-and-biology.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/the-science-behind-obesity/disease-understanding/obesity-is-a-chronic-and-increasingly-prevalent-disease.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/the-science-behind-obesity/disease-understanding/multiple-complications-are-associated-with-obesity.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/the-science-behind-obesity/experts-opinion.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/the-science-behind-obesity/toolbox.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/disease-management.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/disease-management/weight-management.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/disease-management/weight-management/obesity-management-guidelines.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/disease-management/weight-management/current-options-for-the-management-of-obesity.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/disease-management/weight-management/step-clinical-trials-showed-the-benefits-of-semaglutide.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/disease-management/weight-management/semaglutide-safety-profile-in-the-step-trials.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/disease-management/experts-opinion.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/disease-management/toolbox.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/the-conversation-starts-here.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/the-conversation-starts-here/starting-the-weight-conversation.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/the-conversation-starts-here/starting-the-weight-conversation/managing-patients-with-obesity-involves-addressing-the-bias-and-barriers-to-care.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/the-conversation-starts-here/experts-opinion.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/the-conversation-starts-here/toolbox.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/know-obesity-by-heart.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/know-obesity-by-heart/obesity-and-the-global-burden-of-cardiovascular-disease.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/know-obesity-by-heart/obesity-and-cardiovascular-disease.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/know-obesity-by-heart/residual-cardiovascular-risk-rising-from-obesity.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/know-obesity-by-heart/weight-loss-and-benefits-for-cardiovascular-disease-cvd.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/know-obesity-by-heart/interventions-to-address-cardiovascular-risk.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/know-obesity-by-heart/how-to-effectively-communicate-the-cardiovascular-risks-with-your-patients.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/know-obesity-by-heart/the-select-trial.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/obesity-clinic-set-up.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/independent-medical-education.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/bmi-obesity-risk-calculator.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/obesity-and-health.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/obesity-and-health/obesity-in-children-and-adolescents.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/obesity-and-health/a-chronic-disease-the-health-impacts-of-obesity.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/obesity-and-health/complications-and-comorbidities-of-obesity.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/obesity-and-health/benefits-of-10-15-percent-weight-loss-on-health.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/obesity-and-health/pathophysiology-of-obesity-all-about-the-science-to-obesity.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/obesity-and-health/obesity-and-covid-19.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/obesity-and-health/obesity-and-covid-19-where-can-i-learn-more.htmlhttps://pro.novonordisk.ae/disease-area/weightfluencers-hub/obesity-and-health/sd-28286.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-academy.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-academy/type-2-diabetes-aetiology-and-pathophysiology.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-academy/symptoms-diagnosis-and-complications.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-academy/complications-of-diabetes.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-academy/complications-of-diabetes-cardiovascular-disease.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-academy/insights-from-cardiovascular-outcome-trials-in-type-2-diabetes.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-academy/diabetes-related-complications-chronic-kidney-disease.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-academy/diabetes-related-complications-diabetic-retinopathy.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-academy/complications-of-diabetes-cognitive-impairment.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-academy/principles-of-management-for-patient-centred-care-overview.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-academy/principles-of-management-for-patient-centred-care-lifestyle-management.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-academy/management-of-hyperglycaemia-in-type-2-diabetes.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-academy/newer-treatments-for-type-2-diabetes.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-and-cvd.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-and-cvd/stratifying-and-reducing-cv-risk-in-patients-with-t2d.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-and-cvd/interact-module-2a.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-and-cvd/interact-module-2b.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-and-cvd/interact-module-3.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-and-cvd/introduction-to-stroke.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-and-cvd/stroke-and-t2d-a-relationship-between-two-diseases.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-and-cvd/potential-protection-against-stroke-with-glp-1-receptor-agonists.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-and-cvd/stroke-in-diabetes-patient-journey.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-and-cvd/medical-education-for-diabetes-and-chronic-kidney-disease-1.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-and-cvd/medical-education-for-diabetes-and-chronic-kidney-disease-2.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-and-cvd/medical-education-for-diabetes-and-chronic-kidney-disease-3.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-and-cvd/medical-education-for-diabetes-and-chronic-kidney-disease-4.htmlhttps://pro.novonordisk.ae/disease-area/diabetes-hub/diabetes-and-ramadan.htmlhttps://pro.novonordisk.ae/disease-area/haemostasis-bleeding-disorders.htmlhttps://pro.novonordisk.ae/disease-area/haemostasis-bleeding-disorders/severe-postpartum-haemorrhage.htmlhttps://pro.novonordisk.ae/disease-area/haemostasis-bleeding-disorders/heavy-menstrual-bleeding-in-women-with-glanzmanns-thrombasthenia-and-factor-seven-deficiency.htmlhttps://pro.novonordisk.ae/disease-area/haemostasis-bleeding-disorders/acquired-haemophilia.htmlhttps://pro.novonordisk.ae/disease-area/alzheimer-disease.htmlhttps://pro.novonordisk.ae/disease-area/alzheimer-disease/alzheimer-disease-awareness-and-risk-factors.htmlhttps://pro.novonordisk.ae/disease-area/alzheimer-disease/is-there-a-link-between-diabetes-and-alzheimer-risk.htmlhttps://pro.novonordisk.ae/disease-area/alzheimer-disease/is-obesity-associated-with-alzheimer-risk.htmlhttps://pro.novonordisk.ae/disease-area/alzheimer-disease/what-can-we-do-to-address-alzheimers-disease.htmlhttps://pro.novonordisk.ae/products.htmlhttps://pro.novonordisk.ae/products/All-Products.htmlhttps://pro.novonordisk.ae/products/wegovy.htmlhttps://pro.novonordisk.ae/products/wegovy/wegovy-efficacy-video.htmlhttps://pro.novonordisk.ae/products/rybelsus.htmlhttps://pro.novonordisk.ae/products/rybelsus/clinical-Insights-real-patient-cases-old/examining-the-efficacy-of-rybelsus-vs-liraglutide-as-an-add-on-to-sglt-two-i-in-a-real-life-clinical-setting.htmlhttps://pro.novonordisk.ae/products/rybelsus/clinical-Insights-real-patient-cases-old/elearning.htmlhttps://pro.novonordisk.ae/products/rybelsus/clinical-Insights-real-patient-cases-old/injectare.htmlhttps://pro.novonordisk.ae/products/rybelsus/clinical-insights-and-real-patient-cases/examining-the-efficacy-of-rybelsus-vs-liraglutide-as-an-add-on-to-sglt-two-i-in-a-real-life-clinical-setting-old-old.htmlhttps://pro.novonordisk.ae/products/rybelsus/clinical-insights-and-real-patient-cases/examining-the-efficacy-of-rybelsus-vs-liraglutide-as-an-add-on-to-sglt-two-i-in-a-real-life-clinical-setting.htmlhttps://pro.novonordisk.ae/products/rybelsus/events-hub/injectare.htmlhttps://pro.novonordisk.ae/products/rybelsus/events-hub/elearning.htmlhttps://pro.novonordisk.ae/products/rybelsus/mode-of-action.htmlhttps://pro.novonordisk.ae/products/rybelsus/efficacy.htmlhttps://pro.novonordisk.ae/products/rybelsus/cardio-metabolic-risk-reduction-in-type-2-diabetes.htmlhttps://pro.novonordisk.ae/products/rybelsus/safety-and-tolerability.htmlhttps://pro.novonordisk.ae/products/rybelsus/dosage-and-administration.htmlhttps://pro.novonordisk.ae/products/rybelsus/tools.htmlhttps://pro.novonordisk.ae/products/rybelsus/clinical-insights-real-patient-cases.htmlhttps://pro.novonordisk.ae/products/rybelsus/clinical-insights-real-patient-cases/examining-the-efficacy-of-rybelsus-vs-liraglutide-as-an-add-on-to-sglt2i-in-a-real-life-clinical-setting.htmlhttps://pro.novonordisk.ae/products/rybelsus/clinical-insights-real-patient-cases/examining-the-efficacy-of-rybelsus-for-newly-diagnosed-type-2-diabetes-in-a-real-life-clinical-setting.htmlhttps://pro.novonordisk.ae/products/rybelsus/clinical-insights-real-patient-cases/examining-the-efficacy-of-rybelsus-vs-empagliflozin-in-a-real-life-clinical-setting.htmlhttps://pro.novonordisk.ae/products/rybelsus/clinical-insights-real-patient-cases/examining-the-efficacy-and-safety-of-rybelsus-vs-sitagliptin-in-a-real-life-clinical-setting.htmlhttps://pro.novonordisk.ae/products/rybelsus/lets-talk.htmlhttps://pro.novonordisk.ae/products/rybelsus/resources.htmlhttps://pro.novonordisk.ae/products/rybelsus/resources/rybelsus-anniversary-welcome-note-and-introduction.htmlhttps://pro.novonordisk.ae/products/rybelsus/resources/oral-semaglutide-the-only-pill-of-its-kind.htmlhttps://pro.novonordisk.ae/products/rybelsus/resources/the-bigger-picture-early-control-matters.htmlhttps://pro.novonordisk.ae/products/rybelsus/resources/time-to-focus-on-optimal-utilization-of-glp-one-ras-in-clinical-practice.htmlhttps://pro.novonordisk.ae/products/rybelsus/resources/patient-centric-practicalities-with-oral-semaglutide-from-the-clinic.htmlhttps://pro.novonordisk.ae/products/rybelsus/resources/a-patient-centered-approach-with-oral-semaglutide.htmlhttps://pro.novonordisk.ae/products/rybelsus/resources/insights-from-the-clinic-a-case-based-discussion.htmlhttps://pro.novonordisk.ae/products/rybelsus/resources/panel-discussion-questions-and-answers.htmlhttps://pro.novonordisk.ae/products/rybelsus/experience-rybelsus.htmlhttps://pro.novonordisk.ae/products/ozempic.htmlhttps://pro.novonordisk.ae/products/ozempic/about-ozempic.htmlhttps://pro.novonordisk.ae/products/ozempic/efficacy.htmlhttps://pro.novonordisk.ae/products/ozempic/safety-and-tolerability.htmlhttps://pro.novonordisk.ae/products/ozempic/cardiovascular-benefit.htmlhttps://pro.novonordisk.ae/products/ozempic/dosing-and-administration.htmlhttps://pro.novonordisk.ae/products/ozempic/lets-talk.htmlhttps://pro.novonordisk.ae/products/ozempic/experience-ozempic.htmlhttps://pro.novonordisk.ae/products/tresiba.htmlhttps://pro.novonordisk.ae/products/tresiba/mode-of-action.htmlhttps://pro.novonordisk.ae/products/tresiba/safety-and-efficacy.htmlhttps://pro.novonordisk.ae/products/tresiba/dosage-and-administration.htmlhttps://pro.novonordisk.ae/products/tresiba/tools-and-resources.htmlhttps://pro.novonordisk.ae/products/tresiba/lets-talk.htmlhttps://pro.novonordisk.ae/products/novoseven.htmlhttps://pro.novonordisk.ae/products/novoseven/severe-postpartum-haemorrhage.htmlhttps://pro.novonordisk.ae/products/novoseven/effective-bleed-control-for-people-with-ah.htmlhttps://pro.novonordisk.ae/products/novoseven/lets-talk.htmlhttps://pro.novonordisk.ae/products/what-are-the-products-of-semaglutide.htmlhttps://pro.novonordisk.ae/products/what-are-the-products-of-semaglutide/semaglutide-portfolio.htmlhttps://pro.novonordisk.ae/products/saxenda.htmlhttps://pro.novonordisk.ae/products/saxenda/mode-of-action.htmlhttps://pro.novonordisk.ae/products/saxenda/efficacy.htmlhttps://pro.novonordisk.ae/products/saxenda/safety-and-tolerability.htmlhttps://pro.novonordisk.ae/products/saxenda/dosage-and-administration.htmlhttps://pro.novonordisk.ae/products/saxenda/tools-and-resources.htmlhttps://pro.novonordisk.ae/products/saxenda/let-s-talk.htmlhttps://pro.novonordisk.ae/products/ryzodeg.htmlhttps://pro.novonordisk.ae/products/ryzodeg/mode-of-action.htmlhttps://pro.novonordisk.ae/products/ryzodeg/safety-and-efficacy.htmlhttps://pro.novonordisk.ae/products/ryzodeg/dosage-and-administration.htmlhttps://pro.novonordisk.ae/products/ryzodeg/arise-real-world-study.htmlhttps://pro.novonordisk.ae/products/ryzodeg/arise-real-world-study/hba1c-significantly-reduced-with-ryzodeg.htmlhttps://pro.novonordisk.ae/products/ryzodeg/arise-real-world-study/fpg-significantly-reduced-with-ryzodeg.htmlhttps://pro.novonordisk.ae/products/ryzodeg/arise-real-world-study/basal-insulin-dose-and-body-weight-significantly-reduced-with-ryzodeg.htmlhttps://pro.novonordisk.ae/products/ryzodeg/tools-and-resources.htmlhttps://pro.novonordisk.ae/products/ryzodeg/lets-talk.htmlhttps://pro.novonordisk.ae/products/novofine.htmlhttps://pro.novonordisk.ae/products/welcome-to-ozempic-old/about-ozempic.htmlhttps://pro.novonordisk.ae/products/welcome-to-ozempic-old/efficacy.htmlhttps://pro.novonordisk.ae/products/welcome-to-ozempic-old/safety-tolerability.htmlhttps://pro.novonordisk.ae/products/welcome-to-ozempic-old/cardiovascular-benefit.htmlhttps://pro.novonordisk.ae/products/welcome-to-ozempic-old/dosing-administration.htmlhttps://pro.novonordisk.ae/products/welcome-to-ozempic-old/let-s-talk.htmlhttps://pro.novonordisk.ae/products/welcome-to-ozempic-old1/about-ozempic.htmlhttps://pro.novonordisk.ae/products/welcome-to-ozempic-old1/efficacy.htmlhttps://pro.novonordisk.ae/products/welcome-to-ozempic-old1/safety-tolerability.htmlhttps://pro.novonordisk.ae/products/welcome-to-ozempic-old1/cardiovascular-benefit.htmlhttps://pro.novonordisk.ae/products/welcome-to-ozempic-old1/dosing-administration.htmlhttps://pro.novonordisk.ae/products/welcome-to-ozempic-old1/let-s-talk.htmlhttps://pro.novonordisk.ae/scientific-hub.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2024.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2024/easd-2024-registration-form.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2024/post-esad-2024-resources.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2024/daily-digest.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2024/daily-digest/day-1.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2024/daily-digest/day-2.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2024/daily-digest/day-3.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2024/daily-digest/day-4.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/eco-2024-resources.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/eco-2024-resources/long-term-weight-loss-in-the-select-trial.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/eco-2024-resources/serious-adverse-events-and-safety-profile-of-semaglutide-vs-placebo-in-the-select-study.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/eco-2024-resources/relevance-of-body-weight-and-weight-change-on-cardiovascular.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/era-2024-resources.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/era-2024-resources/effect-of-semaglutide-on-kidney-outcomes-in-people-with-overweight-or-obesity-and-established-cardiovascular-disease-in-the-select-trial.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/acc-2024-resources.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/acc-2024-resources/patient-and-cardiologist-perspectives-on-the-treatment-of-atherosclerotic-cardiovascular-disease-and-obesity.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/acc-2024-resources/effect-of-semaglutide-on-cardiorenal-outcomes-by-baseline-body-mass-index-and-prior-cardiovascular-disease-pooled-analysis-of-sustain-6-and-pioneer-6.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/aha-2023-resources.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/aha-2023-resources/semaglutide-and-cardiovascular-outcomes-in-patients-with-overweight-or-obesity-and-cardiovascular-disease-who-do-not-have-diabetes.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/aha-2023-resources/effect-of-semaglutide-on-kidney-outcomes-in-people-with-overweight-or-obesity-and-established-cardiovascular-disease-in-the-select-trial.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/esc-2023-resources.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/esc-2023-resources/semaglutide-in-patients-with-heart-failure-with-preserved-ejection-fraction-and-obesity.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/esc-2023-resources/cardioprotective-pharmacotherapy-in-patients-with-type-2-diabetes-across-the-middle-east-and-africa-the-pact-mea-study.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/esc-2023-resources/effects-of-once-weekly-semaglutide-on-major-adverse-cardiovascular-events-in-patients-with-type-2-diabetes-and-polyvascular-disease-a-post-hoc-analysis-of-the-sutain-6-trial.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/easd-2023-resources.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/easd-2023-resources/benefit-of-dual-therapy-with-glp-1-ra-and-sglt2i-on-cardiovascular-outcomes-in-type-2-diabetes.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/easd-2023-resources/benefit-of-dual-therapy-with-glp-1-ra-and-sglt2i-on-renal-outcomes-in-type-2-diabetes.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/asn-2023-resources.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/asn-2023-resources/treatment-utilization-and-disease-burden-associated-with-chronic-kidney-disease-progression-in-patients-with-type-2-diabetes.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/esc-preventive-cardiology-2022.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/esc-preventive-cardiology-2022/effects-of-once-weekly-semaglutide-on-coronary-artery-disease-ou.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/era-2023-resources.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/era-2023-resources/the-rationale-design-and-baseline-data-of-flow.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/era-2023-resources/kidney-disease-outcomes-with-semaglutide-versus-placebo-across-baseline-kidgo-risk-categories-a-post-hoc-analysis-of-sustain-6.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/previous-international-congresses-resources/insights-from-the-sustain-6-trial.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/daily-digest.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/daily-digest/day-1.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/daily-digest/day-2.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/daily-digest/day-3.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/daily-digest/1st-extended-coverage.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/daily-digest/2nd-extended-coverage.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/daily-digest/3rd-extended-coverage.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/daily-digest/4th-extended-coverage.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/daily-digest/5th-extended-coverage.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/daily-digest/6th-extended-coverage.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/daily-digest/7th-extended-coverage.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2024/post-congress-resources.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2024.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2024/daily-digest.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2024/daily-digest/day-1.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2024/daily-digest/day-2.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2024/daily-digest/day-3.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2024/daily-digest/day-4.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2024/post-congress-resources.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2024/post-congress-resources/changes-in-visceral-adiposity-modify-the-impact-of-weight-loss.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2024/post-congress-resources/long-term-weight-loss-in-the-select-trial.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2024/post-congress-resources/step-10-trial-semaglutide-2-4-mg-provided-a-superior-reduction-vs-placebo.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2024/post-congress-resources/semaglutide-2-4-mg-efficacy-and-safety-in-people-with-obesity.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2024/post-congress-resources/serious-adverse-events-and-safety-profile-of-semaglutide-vs-placebo.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2024/post-congress-resources/heterogeneity-in-the-association-between-different-adiposity-measures.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2024/post-congress-resources/exploring-potential-treatment-targets-using-real-world-data.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2024/eco-2024-registration-form.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2024/relevance-of-body-weight-and-weight-change-on-cardiovascular-benefit-with-semaglutide.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2023.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2023/daily-digest.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2023/daily-digest/day-1.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2023/daily-digest/day-2.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2023/daily-digest/day-3.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2023/daily-digest/day-4.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2023/post-easd-2023-webinar.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2023/59th-annual-meeting-european-association-for-the-study-of-diabetes-easd-2023.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2023/recorded-easd-2023-webinar.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2023/revisit-easd-2023.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/uoc-2023.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2022.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/acc-2025.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/acc-2025/soul-study-highlights.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/acc-2025/stride-study-highlights.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/acc-2025/acc-2025-registration-form.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/acc-2025/soul-study-disclaimer.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/acc-2025/stride-study-disclaimer.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/acc-2025-disclaimer.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2025.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2025/daily-digest.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2025/daily-digest/day-1.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2025/daily-digest/day-2.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2025/daily-digest/day-3.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2025/daily-digest/day-4.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2025/registration-form.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2025/registration-form-disclaimer.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2025/daily-digest-disclaimer.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/eco-2025-disclaimer.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2025.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2025/the-full-impact-of-semaglutide-7-2-mg-in-obesity-care.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2025/cv-outcomes-in-incretin-based-therapies.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/easd-2025/semaglutide-cardioprotection-and-food-noise.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/ESC_2025.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/ESC_2025/unravelling-cardiovascular-inflammation-in-ascvd.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/ESC_2025/a-change-of-heart.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/ESC_2025/glp-1ras-in-obesity-related-hfpef.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2025_old.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2025_old/unravelling-cardiovascular-inflammation-in-ascvd.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2025_old/A_change_of_heart.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/esc-2025_old/GLP-1RAs_in_obesity-related_HFpEF.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/test_rajl.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/test_rajl/unravelling-cardiovascular-inflammation-in-ascvd.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/test_rajl/A_change_of_heart.htmlhttps://pro.novonordisk.ae/scientific-hub/congresses/test_rajl/GLP-1RAs_in_obesity-related_HFpEF.htmlhttps://pro.novonordisk.ae/scientific-hub/novo-nordisk-medical-education.htmlhttps://pro.novonordisk.ae/scientific-hub/novo-nordisk-medical-education/diabetes-and-pregnancy.htmlhttps://pro.novonordisk.ae/scientific-hub/novo-nordisk-medical-education/expect-trial-more-options-for-hyperglycemia-in-pregnancy.htmlhttps://pro.novonordisk.ae/scientific-hub/novo-nordisk-medical-education/diabetes-and-ramadan-insights.htmlhttps://pro.novonordisk.ae/scientific-hub/novo-nordisk-medical-education/evolution-of-type-2-diabetes-management-guidelines-beyond-hba1c.htmlhttps://pro.novonordisk.ae/scientific-hub/novo-nordisk-medical-education/diabetes-ramadan-meet-the-expert.htmlhttps://pro.novonordisk.ae/scientific-hub/novo-nordisk-medical-education/select.htmlhttps://pro.novonordisk.ae/scientific-hub/novo-nordisk-medical-education/when-its-time-for-insulin-choose-tresiba.htmlhttps://pro.novonordisk.ae/scientific-hub/novo-nordisk-medical-education/diabetes-clinical-case-discussion-by-experts.htmlhttps://pro.novonordisk.ae/scientific-hub/novo-nordisk-medical-education/diabetes-clinical-case-discussion-by-experts/clinical-case-discussion-by-dr-aftab.htmlhttps://pro.novonordisk.ae/scientific-hub/novo-nordisk-medical-education/diabetes-clinical-case-discussion-by-experts/clinical-case-discussion-by-dr-lina.htmlhttps://pro.novonordisk.ae/scientific-hub/novo-nordisk-medical-education/empowering-hearts-evidence-based-cardiovascular-care-for-type-2-diabetes.htmlhttps://pro.novonordisk.ae/scientific-hub/novo-nordisk-medical-education/flow-trial.htmlhttps://pro.novonordisk.ae/scientific-hub/novo-nordisk-medical-education/steer-rwe-study.htmlhttps://pro.novonordisk.ae/scientific-hub/novo-nordisk-medical-education/improved-weight-loss-with-semaglutide.htmlhttps://pro.novonordisk.ae/scientific-hub/novo-nordisk-medical-education/reducing-food-noise-with-semaglutide.htmlhttps://pro.novonordisk.ae/scientific-hub/novo-nordisk-medical-education/ascvd-and-systemic-inflammation.htmlhttps://pro.novonordisk.ae/scientific-hub/novo-nordisk-medical-education/essence-trial-overview-and-part-1-results.htmlhttps://pro.novonordisk.ae/scientific-hub/novo-nordisk-medical-education/step-up-semaglutide-improves-body-composition-with-preserved-muscle-function.htmlhttps://pro.novonordisk.ae/scientific-hub/independent-medical-education.htmlhttps://pro.novonordisk.ae/scientific-hub/independent-medical-education/obesity.htmlhttps://pro.novonordisk.ae/scientific-hub/independent-medical-education/obesity/obesity-ecme-collection.htmlhttps://pro.novonordisk.ae/scientific-hub/independent-medical-education/diabetes.htmlhttps://pro.novonordisk.ae/scientific-hub/independent-medical-education/diabetes/idf-diabetes-management.htmlhttps://pro.novonordisk.ae/scientific-hub/independent-medical-education/diabetes/idf-diabetes-management/course-registration.htmlhttps://pro.novonordisk.ae/scientific-hub/independent-medical-education/diabetes/idf-diabetes-management/course-registration/idf_disclaimer.htmlhttps://pro.novonordisk.ae/scientific-hub-new.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2024.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2024/easd-2024-registration-form.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2024/post-esad-2024-resources.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2024/daily-digest.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2024/daily-digest/day-1.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2024/daily-digest/day-2.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2024/daily-digest/day-3.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2024/daily-digest/day-4.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/eco-2024-resources.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/eco-2024-resources/long-term-weight-loss-in-the-select-trial.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/eco-2024-resources/serious-adverse-events-and-safety-profile-of-semaglutide-vs-placebo-in-the-select-study.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/eco-2024-resources/relevance-of-body-weight-and-weight-change-on-cardiovascular.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/era-2024-resources.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/era-2024-resources/effect-of-semaglutide-on-kidney-outcomes-in-people-with-overweight-or-obesity-and-established-cardiovascular-disease-in-the-select-trial.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/acc-2024-resources.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/acc-2024-resources/patient-and-cardiologist-perspectives-on-the-treatment-of-atherosclerotic-cardiovascular-disease-and-obesity.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/acc-2024-resources/effect-of-semaglutide-on-cardiorenal-outcomes-by-baseline-body-mass-index-and-prior-cardiovascular-disease-pooled-analysis-of-sustain-6-and-pioneer-6.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/aha-2023-resources.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/aha-2023-resources/semaglutide-and-cardiovascular-outcomes-in-patients-with-overweight-or-obesity-and-cardiovascular-disease-who-do-not-have-diabetes.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/aha-2023-resources/effect-of-semaglutide-on-kidney-outcomes-in-people-with-overweight-or-obesity-and-established-cardiovascular-disease-in-the-select-trial.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/esc-2023-resources.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/esc-2023-resources/semaglutide-in-patients-with-heart-failure-with-preserved-ejection-fraction-and-obesity.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/esc-2023-resources/cardioprotective-pharmacotherapy-in-patients-with-type-2-diabetes-across-the-middle-east-and-africa-the-pact-mea-study.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/esc-2023-resources/effects-of-once-weekly-semaglutide-on-major-adverse-cardiovascular-events-in-patients-with-type-2-diabetes-and-polyvascular-disease-a-post-hoc-analysis-of-the-sutain-6-trial.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/easd-2023-resources.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/easd-2023-resources/benefit-of-dual-therapy-with-glp-1-ra-and-sglt2i-on-cardiovascular-outcomes-in-type-2-diabetes.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/easd-2023-resources/benefit-of-dual-therapy-with-glp-1-ra-and-sglt2i-on-renal-outcomes-in-type-2-diabetes.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/asn-2023-resources.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/asn-2023-resources/treatment-utilization-and-disease-burden-associated-with-chronic-kidney-disease-progression-in-patients-with-type-2-diabetes.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/esc-preventive-cardiology-2022.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/esc-preventive-cardiology-2022/effects-of-once-weekly-semaglutide-on-coronary-artery-disease-ou.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/era-2023-resources.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/era-2023-resources/the-rationale-design-and-baseline-data-of-flow.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/era-2023-resources/kidney-disease-outcomes-with-semaglutide-versus-placebo-across-baseline-kidgo-risk-categories-a-post-hoc-analysis-of-sustain-6.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/previous-international-congresses-resources/insights-from-the-sustain-6-trial.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/daily-digest.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/daily-digest/day-1.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/daily-digest/day-2.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/daily-digest/day-3.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/daily-digest/1st-extended-coverage.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/daily-digest/2nd-extended-coverage.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/daily-digest/3rd-extended-coverage.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/daily-digest/4th-extended-coverage.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/daily-digest/5th-extended-coverage.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/daily-digest/6th-extended-coverage.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/daily-digest/7th-extended-coverage.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2024/post-congress-resources.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2024.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2024/daily-digest.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2024/daily-digest/day-1.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2024/daily-digest/day-2.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2024/daily-digest/day-3.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2024/daily-digest/day-4.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2024/post-congress-resources.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2024/post-congress-resources/changes-in-visceral-adiposity-modify-the-impact-of-weight-loss.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2024/post-congress-resources/long-term-weight-loss-in-the-select-trial.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2024/post-congress-resources/step-10-trial-semaglutide-2-4-mg-provided-a-superior-reduction-vs-placebo.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2024/post-congress-resources/semaglutide-2-4-mg-efficacy-and-safety-in-people-with-obesity.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2024/post-congress-resources/serious-adverse-events-and-safety-profile-of-semaglutide-vs-placebo.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2024/post-congress-resources/heterogeneity-in-the-association-between-different-adiposity-measures.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2024/post-congress-resources/exploring-potential-treatment-targets-using-real-world-data.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2024/eco-2024-registration-form.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2024/relevance-of-body-weight-and-weight-change-on-cardiovascular-benefit-with-semaglutide.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2023.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2023/daily-digest.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2023/daily-digest/day-1.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2023/daily-digest/day-2.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2023/daily-digest/day-3.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2023/daily-digest/day-4.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2023/post-easd-2023-webinar.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2023/59th-annual-meeting-european-association-for-the-study-of-diabetes-easd-2023.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2023/recorded-easd-2023-webinar.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2023/revisit-easd-2023.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/uoc-2023.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2022.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/acc-2025.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/acc-2025/soul-study-highlights.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/acc-2025/stride-study-highlights.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/acc-2025/acc-2025-registration-form.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/acc-2025/soul-study-disclaimer.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/acc-2025/stride-study-disclaimer.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2025.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2025/daily-digest.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2025/daily-digest/day-1.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2025/daily-digest/day-2.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2025/daily-digest/day-3.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2025/daily-digest/day-4.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2025/registration-form.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2025/registration-form-disclaimer.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/eco-2025/daily-digest-disclaimer.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2025.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2025/the-full-impact-of-semaglutide-7-2-mg-in-obesity-care.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2025/cv-outcomes-in-incretin-based-therapies.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/easd-2025/semaglutide-cardioprotection-and-food-noise.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2025.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2025/unravelling-cardiovascular-inflammation-in-ascvd.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2025/A_change_of_heart.htmlhttps://pro.novonordisk.ae/scientific-hub-new/congresses/esc-2025/GLP-1RAs_in_obesity-related_HFpEF.htmlhttps://pro.novonordisk.ae/scientific-hub-new/independent-medical-education.htmlhttps://pro.novonordisk.ae/scientific-hub-new/independent-medical-education/obesity.htmlhttps://pro.novonordisk.ae/scientific-hub-new/independent-medical-education/obesity/obesity-ecme-collection.htmlhttps://pro.novonordisk.ae/scientific-hub-new/independent-medical-education/diabetes.htmlhttps://pro.novonordisk.ae/scientific-hub-new/independent-medical-education/diabetes/idf-diabetes-management.htmlhttps://pro.novonordisk.ae/scientific-hub-new/independent-medical-education/diabetes/idf-diabetes-management/course-registration.htmlhttps://pro.novonordisk.ae/scientific-hub-new/independent-medical-education/diabetes/idf-diabetes-management/course-registration/idf_disclaimer.htmlhttps://pro.novonordisk.ae/scientific-hub-new/novo-nordisk-medical-education_old.htmlhttps://pro.novonordisk.ae/scientific-hub-new/novo-nordisk-medical-education_old/diabetes-and-pregnancy.htmlhttps://pro.novonordisk.ae/scientific-hub-new/novo-nordisk-medical-education_old/expect-trial-more-options-for-hyperglycemia-in-pregnancy.htmlhttps://pro.novonordisk.ae/scientific-hub-new/novo-nordisk-medical-education_old/evolution-of-type-2-diabetes-management-guidelines-beyond-hba1c.htmlhttps://pro.novonordisk.ae/scientific-hub-new/novo-nordisk-medical-education_old/diabetes-ramadan-meet-the-expert.htmlhttps://pro.novonordisk.ae/scientific-hub-new/novo-nordisk-medical-education_old/when-its-time-for-insulin-choose-tresiba.htmlhttps://pro.novonordisk.ae/scientific-hub-new/novo-nordisk-medical-education_old/diabetes-clinical-case-discussion-by-experts.htmlhttps://pro.novonordisk.ae/scientific-hub-new/novo-nordisk-medical-education_old/diabetes-clinical-case-discussion-by-experts/clinical-case-discussion-by-dr-aftab.htmlhttps://pro.novonordisk.ae/scientific-hub-new/novo-nordisk-medical-education_old/diabetes-clinical-case-discussion-by-experts/clinical-case-discussion-by-dr-lina.htmlhttps://pro.novonordisk.ae/scientific-hub-new/novo-nordisk-medical-education_old/empowering-hearts-evidence-based-cardiovascular-care-for-type-2-diabetes.htmlhttps://pro.novonordisk.ae/scientific-hub-new/novo-nordisk-medical-education_old/select.htmlhttps://pro.novonordisk.ae/scientific-hub-new/novo-nordisk-medical-education_old/flow-trial.htmlhttps://pro.novonordisk.ae/scientific-hub-new/novo-nordisk-medical-education_old/steer-rwe-study.htmlhttps://pro.novonordisk.ae/scientific-hub-new/novo-nordisk-medical-education_old/improved-weight-loss-with-semaglutide.htmlhttps://pro.novonordisk.ae/scientific-hub-new/novo-nordisk-medical-education_old/reducing-food-noise-with-semaglutide.htmlhttps://pro.novonordisk.ae/scientific-hub-new/novo-nordisk-medical-education_old/ascvd-and-systemic-inflammation.htmlhttps://pro.novonordisk.ae/scientific-hub-new/novo-nordisk-medical-education_old/essence-semaglutide-in-metabolic-dysfunction-associated-steato.htmlhttps://pro.novonordisk.ae/events.htmlhttps://pro.novonordisk.ae/events/5th-uae-obesity-conference-uoc.htmlhttps://pro.novonordisk.ae/events/5th-uae-obesity-conference-uoc/day-1.htmlhttps://pro.novonordisk.ae/events/5th-uae-obesity-conference-uoc/day-2.htmlhttps://pro.novonordisk.ae/events/efms.htmlhttps://pro.novonordisk.ae/events/efms/rybelsus.htmlhttps://pro.novonordisk.ae/events/obesity-excellence.htmlhttps://pro.novonordisk.ae/events/upcoming-events.htmlhttps://pro.novonordisk.ae/events/previous-events.htmlhttps://pro.novonordisk.ae/events/hero-summit.htmlhttps://pro.novonordisk.ae/events/wegovy-scientific-communication.htmlhttps://pro.novonordisk.ae/events/ice-congress.htmlhttps://pro.novonordisk.ae/events/the-heart-of-the-matter.htmlhttps://pro.novonordisk.ae/events/the-heart-of-the-matter/case-study-2.htmlhttps://pro.novonordisk.ae/events/the-heart-of-the-matter/case-study-1.htmlhttps://pro.novonordisk.ae/events/the-heart-of-the-matter/inspiring-change-learnings-from-cardio-metabolic-experts.htmlhttps://pro.novonordisk.ae/events/the-heart-of-the-matter/q-and-a.htmlhttps://pro.novonordisk.ae/events/the-heart-of-the-matter/addressing-residual-cv-risk-in-ascvd-patients-with-obesity.htmlhttps://pro.novonordisk.ae/events/the-heart-of-the-matter/weight-loss-vs-direct-molecular-effects-can-we-separate-the-impact.htmlhttps://pro.novonordisk.ae/events/the-heart-of-the-matter/select-trial-breakthrough-wegovy-weight-loss-and-mace-reduction-a-new-era.htmlhttps://pro.novonordisk.ae/events/the-heart-of-the-matter/mastering-use-of-semaglutide-2-4-mg-practical-insights-for-optimal-use.htmlhttps://pro.novonordisk.ae/events/the-heart-of-the-matter/heart-failure-in-obesity-the-new-growing-evidence.htmlhttps://pro.novonordisk.ae/events/the-heart-of-the-matter/semaglutide-2-4-mg-use-in-adolescents-real-life-case.htmlhttps://pro.novonordisk.ae/events/the-heart-of-the-matter/q-and-a-1.htmlhttps://pro.novonordisk.ae/events/Legacy-in-Motion-The-Era-Begins.htmlhttps://pro.novonordisk.ae/events/Legacy-in-Motion-The-Era-Begins/registration-form.htmlhttps://pro.novonordisk.ae/events/act-summit.htmlhttps://pro.novonordisk.ae/events/act-summit/day-1.htmlhttps://pro.novonordisk.ae/events/act-summit/day-1/opening-and-introduction.htmlhttps://pro.novonordisk.ae/events/act-summit/day-1/the-link-between-cardio-renal-and-metabolic-disease.htmlhttps://pro.novonordisk.ae/events/act-summit/day-1/where-does-semaglutide-fit-in-the-ckm-management.htmlhttps://pro.novonordisk.ae/events/act-summit/day-1/semaglutide-2-4-mg-from-adolescence-to-adulthood-in-obesity-management.htmlhttps://pro.novonordisk.ae/events/act-summit/day-1/the-weight-of-the-heart.htmlhttps://pro.novonordisk.ae/events/act-summit/day-1/the-expanding-role-of-semaglutide-in-t2d.htmlhttps://pro.novonordisk.ae/events/act-summit/day-1/rethinking-t2d-management-the-semaglutide-revolution.htmlhttps://pro.novonordisk.ae/events/act-summit/day-1/new-horizons-for-treatment-of-ckd-in-people-with-t2d-a-deep-dive-into-flow.htmlhttps://pro.novonordisk.ae/events/act-summit/day-1/the-guidance-to-a-holistic-ckm-management.htmlhttps://pro.novonordisk.ae/events/act-summit/day-1/closing-the-loop-from-a-patient-s-perspective.htmlhttps://pro.novonordisk.ae/events/act-summit/day-1/takeaways-and-closing.htmlhttps://pro.novonordisk.ae/events/act-summit/day-1/panel-discussion-1.htmlhttps://pro.novonordisk.ae/events/act-summit/day-1/panel-discussion-2.htmlhttps://pro.novonordisk.ae/events/act-summit/day-1/panel-discussion-4.htmlhttps://pro.novonordisk.ae/events/act-summit/day-1/panel-discussion-3.htmlhttps://pro.novonordisk.ae/events/act-summit/event-highlights.htmlhttps://pro.novonordisk.ae/events/act-summit/disclaimer.htmlhttps://pro.novonordisk.ae/events/validation-redirect-page.htmlhttps://pro.novonordisk.ae/events/ON24-Test.htmlhttps://pro.novonordisk.ae/events/ON24-Test/registration-form.htmlhttps://pro.novonordisk.ae/events/CKM.htmlhttps://pro.novonordisk.ae/events/CKM/registration-form.htmlhttps://pro.novonordisk.ae/events/edec-2026.htmlhttps://pro.novonordisk.ae/materials-library.htmlhttps://pro.novonordisk.ae/coming-soon.htmlhttps://pro.novonordisk.ae/ryzodeg-digital-dosing-test.htmlhttps://pro.novonordisk.ae/cookie-list.htmlhttps://pro.novonordisk.ae/cookie-policy.htmlhttps://pro.novonordisk.ae/privacy-policy.htmlhttps://pro.novonordisk.ae/copyright.htmlhttps://pro.novonordisk.ae/notice-on-data-processing.htmlhttps://pro.novonordisk.ae/404-not-found.htmlhttps://pro.novonordisk.ae/my-profile.htmlhttps://pro.novonordisk.ae/Accdis.htmlhttps://pro.novonordisk.ae/multimedia-resources.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/amycretin-weight-loss-hba1c-type-2-diabetes.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/cagrisema-first-weekly-glp1-amylin-combination.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/cagrisema-linked-to-cardiovascular-risk-reductions-in-obesityweek-analyses.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/eu-approval-first-oral-glp1-ra-to-reduce-cardiovascular-death.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/fda-approval-wegovy-injection-7-2-mg.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/novo-nordisk-and-united-laboratories-license-agreement-for-triple-agonist.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/novo-nordisk-initiative-to-prevent-childhood-obesity.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/omeros-announce-asset-purchase-and-license-agreement-for-omeros.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/oral-amycretin-for-weight-management-into-phase-3-clinical-development.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/oral-semaglutide-25-mg-data-at-obesityweek-2025.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/oral-semaglutide-25-mg-obesityweek-findings.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/oral-semaglutide-25-mg-wegovy-in-a-pill-and-obesity-pipeline.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/ozempic-reduces-heart-attack-stroke-death-by-23-percent.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/phase-3-data-for-amylin-cagrilintide-clinical-programme.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/septerna-and-novo-nordisk-collaborate-on-oral-medicines-for-obesity.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/valo-health-and-novo-nordisk-collaboration-for-cardiometabolic-treatments.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/wegovy-approved-in-the-us-for-the-treatment-of-mash.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/wegovy-data-at-the-2025-american-association-for-the-study-of-liver-diseases.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/wegovy-linked-to-waist-and-bmi-targets.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/wegovy-pill-approved-us-weight-management.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/wegovy-pill-oral-glp1-weight-loss-available.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/wegovy-reduced-food-noise-and-improved-mental-wellbeing.htmlhttps://pro.novonordisk.ae/multimedia-resources/articles-and-news/wegovy-semaglutide-2-4-mg-shows-liver-related-benefits-in-mash.htmlhttps://pro.novonordisk.ae/multimedia-resources/videos-and-podcast.htmlhttps://pro.novonordisk.ae/multimedia-resources/videos-and-podcast/what-do-i-tell-my-patients-ramadan-edition.htmlhttps://pro.novonordisk.ae/test-page.htmlhttps://pro.novonordisk.ae/test-page/empowering-hearts-evidence-based-cardiovascular-care-for-type-2-diabetes.htmlhttps://pro.novonordisk.ae/test-page/severe-postpartum-haemorrhage.htmlhttps://pro.novonordisk.ae/book-a-meeting.htmlhttps://pro.novonordisk.ae/book-a-meeting-email.htmlhttps://pro.novonordisk.ae/search.htmlhttps://pro.novonordisk.ae/consent-form.html